Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q2 2022 Earnings Presentation

37 slides from Walgreens Boots Alliance's earnings presentation, Mar 31, 2022

  1. Slide 1: Fiscal 2022 Second Quarter Results

    Fiscal 2022 Second Quarter Results March 31, 2022 © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 1

  2. Slide 2: Safe Harbor and Non-GAAP

    Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat

  3. Slide 3: Takeaways

    Takeaways • Strong Execution Across Segments • Adj. EPS +26.5% in constant Fx • Robust comparable sales growth across U.S. Pharmacy, U.S. Retail, and Boots UK Retail • Continued Progress on Our Strategic Initiatives • Walgreens Health on pace toward KPI milestones • Strategic review of Boots busines

  4. Slide 4: Leading the Fight Against Pandemic

    Leading the Fight Against Pandemic >62 million vaccinations administered to date >12 million boosters administered to date Vaccinations Largest pediatric vaccine provider in the pharmacy channel >27 million COVID-19 tests completed to date Launched the Walgreens COVID-19 Index to advance rapid detec

  5. Slide 5: To Be the Leading Partner in Reimagining Local Healthcare and Wellbeing for All

    To Be the Leading Partner in Reimagining Local Healthcare and Wellbeing for All Strategic Priorities: 1. Transform and Align the Core 2. Build Our Next Growth Engine with Consumer-Centric Healthcare Solutions 3. Focus the Portfolio; Optimize Capital Allocation 4. Build a High-Performance Culture and

  6. Slide 6: Recent Progress on Strategic Priorities

    Recent Progress on Strategic Priorities  U.S. digital sales +38% in 2Q (116% on a 2-year basis), with 3.9 million same-day pick-up orders  96.1 million myWalgreens members at quarter-end, up 10.9 million since 4Q  102 VillageMD co-located clinics now open, on track toward 200+ by the end of CY22

  7. Slide 7: Delivering and Enabling Value-Based Care Through Consumer-Centric Solutions

    Delivering and Enabling Value-Based Care Through Consumer-Centric Solutions Health Corners Walgreens Health Consumer App and Marketplace Leveraging Our Strong Footprint, Deep Patient Relationships, and Independent Partnerships with Payors and Providers to Improve Outcomes and Lower Costs Along the C

  8. Slide 8: Executing to Build Our Growth Engine

    Executing to Build Our Growth Engine 128% Pro Forma Sales Growth for Walgreens Health Segment in 2Q Health Expansion into new markets including First 11 Health Corners open with Blue Shield Boston, Massachusetts; Jacksonville, Florida; Contract wins with two significant health of California; next 9

  9. Slide 9: WBA Financial Performance

    WBA Financial Performance © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 9

  10. Slide 10: 2Q 2022 Financial Highlights

    2Q 2022 Financial Highlights • Adj. EPS $1.59, +26.5% above prior year in constant Fx • Second quarter performance driven by strong execution in COVID-19 vaccine and testing delivery, U.S. retail sales growth, and continued recovery in International segment performance, partly offset by Walgreens He

  11. Slide 11: 2Q 2022 Financial Highlights

    2Q 2022 Financial Highlights Reported Fx Constant Fx Continuing operations 2Q22 $ in millions (except EPS) B/(W) vs. 2Q21 B/(W) vs. 2Q21 Sales $33,756 + 3.0% + 3.8% Operating income GAAP $1,246 + 49.7% Adjusted $1,657 + 35.3% + 35.9% Net earnings GAAP $883 - 4.1% Adjusted $1,377 + 25.8% + 26.4% EPS

  12. Slide 12: First Half FY22 Financial Highlights

    First Half FY22 Financial Highlights Reported Fx Constant Fx Continuing operations 1H22 $ in millions (except EPS) B/(W) vs. 1H21 B/(W) vs. 1H21 Sales $67,656 + 5.4% + 5.7% Operating income GAAP $2,529 + $2,231 Adjusted $3,434 + 41.8% + 42.1% Net earnings GAAP $4,463 + $3,932 Adjusted $2,833 + 38.7%

  13. Slide 13: United States – Financials

    United States – Financials $ in millions 2Q22 B/(W) vs. 2Q21 1H22 B/(W) vs. 1H21 Sales $27,667 + 1.2% $55,699 + 2.2% Adj. gross profit $6,487 + 13.7% $12,855 + 13.0% Adj. SG&A % of sales 18.3% - 1.2%p 17.7% - 0.7%p Adj. operating income $1,588 + 36.5% $3,277 + 41.4% Adj. operating margin1 5.2% + 1.4

  14. Slide 14: United States – Pharmacy

    United States – Pharmacy 2Q 2Q 1H 1H 2Q22 vs. 2Q21 Total Comparable Total Comparable Pharmacy sales - 3.3% + 7.3% - 1.1% + 7.1% Prescriptions + 3.9% + 4.7% + 4.7% + 5.4% • Comparable pharmacy sales grew +7.3% in the quarter • Comparable scripts +4.7%, benefitting from COVID-19 vaccinations by 275 bp

  15. Slide 15: United States – Retail

    United States – Retail 2Q22 vs. 2Q21 2Q22 1H22 Total retail sales + 14.5% + 12.4% Comparable retail sales + 14.7% + 12.8% • 2Q comp retail sales +14.7%, or excl. tobacco +15.7%; up mid-teens vs. pre-COVID levels ⎯ Transactions +9.5% and basket size +4.7% ⎯ Strength in Health & Wellness +43.3% led by

  16. Slide 16: International – Financials

    International – Financials Constant Fx Constant Fx Continuing operations 2Q22 B/(W) vs. 2Q21 1H22 B/(W) vs. 1H21 $ in millions Sales $5,563 + 7.5% $11,381 + 19.3% Adj. gross profit $1,206 + 15.2% $2,413 + 16.6% Adj. SG&A % of sales 17.6% - 0.1%p 17.8% + 1.5%p Adj. operating income $226 + 60.7% $389

  17. Slide 17: Boots UK – Financials

    Boots UK – Financials 2Q22 vs. 2Q21 (constant Fx) 2Q22 1H22 Pharmacy comp. sales + 3.6% + 6.2% Retail comp. sales + 22.0% + 19.2% • Pharmacy comp. sales +3.6%, reflecting higher levels of pharmacy services • Boots growing retail market share across all categories, led by Beauty • Strengthening retai

  18. Slide 18: Walgreens Health – Financials

    Walgreens Health – Financials Health $ in millions 2Q22 B/(W) vs. 2Q21 1H22 B/(W) vs. 1H21 Sales $527 + $527 $577 + $577 Adj. gross profit $15 + $15 $36 + $36 Adj. SG&A ($92) ($81) ($126) ($111) Adj. operating income ($77) ($66) ($90) ($76) • VillageMD sales of $446M in 2Q, +145% on a pro forma basi

  19. Slide 19: Walgreens Health – Key Metrics

    Walgreens Health – Key Metrics Health Current Status CY22 Goal Lives 1.9M 2M+ Partners (Payor/Provider) 2 5 Sites of Care: Health Corners 47 100+ VillageMD Co-Located Clinics 102 200+ 2Q22 FY22 Goal Sales (Reported) $577M YTD $2.2B Pro Forma Sales Growth YOY: VillageMD 145% Shields 63% Total Walgree

  20. Slide 20: Cash Flow

    Cash Flow B/(W) $ in millions 1H22 vs. 1H21 Operating cash flow $2,184 ($372) Cash capital expenditure ($870) ($178) Free cash flow $1,314 ($550) • YTD cash generation of $2.2B in operating cash flow and $1.3B of free cash flow • Free cash flow was adversely impacted vs. prior year due to decline of

  21. Slide 21: Maintaining Full Year Guidance

    Maintaining Full Year Guidance October 2021 January 2022 March 2022 Adj. EPS Growth (Constant Fx) FY Guidance FY Guidance FY Guidance Base + 4% + 5-7% + 6-8% Healthcare Organic (3)% (3)% (3)% Healthcare M&A (1)% (1)% (2)% Adjusted EPS Flat LSD Growth LSD Growth • Expecting ~31 million vaccinations i

  22. Slide 22: Takeaways

    Takeaways • Strong Execution Across Segments • Adj. EPS +26.5% in constant Fx • Robust comparable sales growth across U.S. Pharmacy, U.S. Retail, and Boots UK Retail • Continued Progress on Our Strategic Initiatives • Walgreens Health on pace toward KPI milestones • Strategic review of Boots busines

  23. Slide 23: © 2022 Walgreens Boots Alliance, Inc. All rights reserved.

    © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 23

  24. Slide 24: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures • The company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  25. Slide 25: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  26. Slide 26: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended February 28, Change vs. 2Q21 Six months ended February 28, Change vs. 1H21 2022 2021 Amount Percent 2022 2021 Amount Percen

  27. Slide 27: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended February 28, Change vs. 2Q21 Six months ended February 28, Change vs. 1H21 2022 2021 Amount Percent 2022 2021 Amount Percen

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended February 28, Change vs. 2Q21 Six months ended February 28, Change vs. 1H21 2022 2021 Amount Percent 2022 2021 Am

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Transformational Cost Management Program charges are costs associated with a formal restructuring plan. These charges are primarily recorded within selling, general an

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 28, 2022 Walgreens Boots United States1 International Walgreens Health Corporate and Other Alliance, Inc. Sales $ 27,667 $ 5,56

  31. Slide 31: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 28, 2021 Walgreens Boots United States1 International Walgreens Health3 Corporate and Other Alliance, Inc. Sales $ 27,344 $ 5,4

  32. Slide 32: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 28, 2022 Walgreens Boots United States1 International Walgreens Health Corporate and Other Alliance, Inc. Sales $ 55,699 $ 11,381

  33. Slide 33: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 28, 2021 Walgreens Boots United States1 International Walgreens Health3 Corporate and Other Alliance, Inc. Sales $ 54,507 $ 9,709

  34. Slide 34: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating income (loss) for United States includes equity earnings (loss) in AmerisourceBergen. As a result of the two-month reporting lag, operating income (loss) for

  35. Slide 35: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended February 28, Six months ended February 28, 2022 2021 2022 2021 Equity earnings (loss) in Ame

  36. Slide 36: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended February 28, 2022 Three months ended February 28, 2021 Earnings before Earnings before income tax Income tax

  37. Slide 37: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended February 28, Six months ended February 28, 2022 2021 2022 2021 Net cash provided by operating activities (GAAP) $ 1,085 $

Walgreens Boots Alliance — Q2 2022 Earnings Presentation on 6ix